Corbus Pharmaceuticals Announces Publication of Phase 2b Cystic Fibrosis Study Patient Demographics and Baseline Disease Characteristics in the Journal of Cystic Fibrosis Phase 2b study of lenabasum for treatment of cystic fibrosis enriched for patients at high risk of pulmonary exacerbationsStudy on target for data readout in late summer 2020 Norwood, MA, June ...

Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2019 Financial Results Topline results for Phase 3 study in systemic sclerosis on schedule for summer of 2020 followed by Phase 2b study results in cystic fibrosis Completed $46 million public offering in February...